334 related articles for article (PubMed ID: 15542854)
1. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein.
Ayton PM; Chen EH; Cleary ML
Mol Cell Biol; 2004 Dec; 24(23):10470-8. PubMed ID: 15542854
[TBL] [Abstract][Full Text] [Related]
2. Functional specificity of CpG DNA-binding CXXC domains in mixed lineage leukemia.
Risner LE; Kuntimaddi A; Lokken AA; Achille NJ; Birch NW; Schoenfelt K; Bushweller JH; Zeleznik-Le NJ
J Biol Chem; 2013 Oct; 288(41):29901-10. PubMed ID: 23990460
[TBL] [Abstract][Full Text] [Related]
3. The AF10 leucine zipper is required for leukemic transformation of myeloid progenitors by MLL-AF10.
DiMartino JF; Ayton PM; Chen EH; Naftzger CC; Young BD; Cleary ML
Blood; 2002 May; 99(10):3780-5. PubMed ID: 11986236
[TBL] [Abstract][Full Text] [Related]
4. A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL.
DiMartino JF; Miller T; Ayton PM; Landewe T; Hess JL; Cleary ML; Shilatifard A
Blood; 2000 Dec; 96(12):3887-93. PubMed ID: 11090074
[TBL] [Abstract][Full Text] [Related]
5. The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.
Birke M; Schreiner S; García-Cuéllar MP; Mahr K; Titgemeyer F; Slany RK
Nucleic Acids Res; 2002 Feb; 30(4):958-65. PubMed ID: 11842107
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2.
Bach C; Mueller D; Buhl S; Garcia-Cuellar MP; Slany RK
Oncogene; 2009 Feb; 28(6):815-23. PubMed ID: 19060922
[TBL] [Abstract][Full Text] [Related]
7. The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis.
Luo RT; Lavau C; Du C; Simone F; Polak PE; Kawamata S; Thirman MJ
Mol Cell Biol; 2001 Aug; 21(16):5678-87. PubMed ID: 11463848
[TBL] [Abstract][Full Text] [Related]
8. MLL-AFX requires the transcriptional effector domains of AFX to transform myeloid progenitors and transdominantly interfere with forkhead protein function.
So CW; Cleary ML
Mol Cell Biol; 2002 Sep; 22(18):6542-52. PubMed ID: 12192052
[TBL] [Abstract][Full Text] [Related]
9. LCX, leukemia-associated protein with a CXXC domain, is fused to MLL in acute myeloid leukemia with trilineage dysplasia having t(10;11)(q22;q23).
Ono R; Taki T; Taketani T; Taniwaki M; Kobayashi H; Hayashi Y
Cancer Res; 2002 Jul; 62(14):4075-80. PubMed ID: 12124344
[TBL] [Abstract][Full Text] [Related]
10. 11q23 translocations split the "AT-hook" cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene.
Zeleznik-Le NJ; Harden AM; Rowley JD
Proc Natl Acad Sci U S A; 1994 Oct; 91(22):10610-4. PubMed ID: 7938000
[TBL] [Abstract][Full Text] [Related]
11. AF4p12, a human homologue to the furry gene of Drosophila, as a novel MLL fusion partner.
Hayette S; Cornillet-Lefebvre P; Tigaud I; Struski S; Forissier S; Berchet A; Doll D; Gillot L; Brahim W; Delabesse E; Magaud JP; Rimokh R
Cancer Res; 2005 Aug; 65(15):6521-5. PubMed ID: 16061630
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation is a key function encoded by MLL fusion partners.
Zeisig BB; Schreiner S; García-Cuéllar MP; Slany RK
Leukemia; 2003 Feb; 17(2):359-65. PubMed ID: 12592336
[TBL] [Abstract][Full Text] [Related]
13. The mixed lineage leukemia (MLL) protein involved in 11q23 translocations contains a domain that binds cruciform DNA and scaffold attachment region (SAR) DNA.
Broeker PL; Harden A; Rowley JD; Zeleznik-Le N
Curr Top Microbiol Immunol; 1996; 211():259-68. PubMed ID: 8585957
[TBL] [Abstract][Full Text] [Related]
14. ELL-associated factor 2 (EAF2), a functional homolog of EAF1 with alternative ELL binding properties.
Simone F; Luo RT; Polak PE; Kaberlein JJ; Thirman MJ
Blood; 2003 Mar; 101(6):2355-62. PubMed ID: 12446457
[TBL] [Abstract][Full Text] [Related]
15. Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation.
Joh T; Kagami Y; Yamamoto K; Segawa T; Takizawa J; Takahashi T; Ueda R; Seto M
Oncogene; 1996 Nov; 13(9):1945-53. PubMed ID: 8934541
[TBL] [Abstract][Full Text] [Related]
16. Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus.
Joh T; Yamamoto K; Kagami Y; Kakuda H; Sato T; Yamamoto T; Takahashi T; Ueda R; Kaibuchi K; Seto M
Oncogene; 1997 Oct; 15(14):1681-7. PubMed ID: 9349501
[TBL] [Abstract][Full Text] [Related]
17. MLL targets SET domain methyltransferase activity to Hox gene promoters.
Milne TA; Briggs SD; Brock HW; Martin ME; Gibbs D; Allis CD; Hess JL
Mol Cell; 2002 Nov; 10(5):1107-17. PubMed ID: 12453418
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional inhibition of p53 by the MLL/MEN chimeric protein found in myeloid leukemia.
Maki K; Mitani K; Yamagata T; Kurokawa M; Kanda Y; Yazaki Y; Hirai H
Blood; 1999 May; 93(10):3216-24. PubMed ID: 10233872
[TBL] [Abstract][Full Text] [Related]
19. Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein.
Yam JW; Jin DY; So CW; Chan LC
Blood; 2004 Feb; 103(4):1445-53. PubMed ID: 14551139
[TBL] [Abstract][Full Text] [Related]
20. Transformation of myeloid progenitors by MLL oncoproteins is dependent on Hoxa7 and Hoxa9.
Ayton PM; Cleary ML
Genes Dev; 2003 Sep; 17(18):2298-307. PubMed ID: 12952893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
